Drugs / Recombinant Human Interferon α1b
Recombinant Human Interferon α1b
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07586904 | May 2025 → Dec 2026 expected | cutaneous melanoma | Xijing Hospital | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05539118 | Sep 2022 → Dec 2024 overdue | melanoma | Xijing Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Interferon α1b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07586904 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant human interferon α1b is a protein with potent antiviral, antiproliferative and immunomodulatory properties.” NCT05539118 ↗ |
| Route | Subcutaneous | “Recombinant Human Interferon α1b Injection: 600 μg administered subcutaneously every other day.” NCT07586904 ↗ |